Akynzeo (netupitant;palonosetron)
- Region
- 🇪🇺 EU
- Active substance
- netupitant;palonosetron
- Company
- Helsinn Birex Pharmaceuticals Ltd
- Status
- Authorised
- Therapeutic area
- Vomiting; Neoplasms; Nausea; Cancer
- CHMP opinion
- Thu 26 Mar 2015
- EU approval
- Wed 27 May 2015
- Application
- EMEA/H/C/003728
- ATC
- A04AA
- Official record
- www.ema.europa.eu
Indication
Akynzeo is indicated in adults for the: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Akynzeo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.